Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: Newsfilter
FDA Approval and Launch of ZEVASKYN: The U.S. FDA has approved ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The commercial launch is underway with the activation of the first treatment center, Lurie Children's Hospital, and patient registrations are being collected through the Abeona Assist program.
Financial Developments: Abeona Therapeutics secured a $155 million sales agreement for a priority review voucher, which will fund operations for over two years as they prepare for ZEVASKYN's market introduction. The company reported a net loss of $12 million for Q1 2025, significantly reduced from $31.6 million in the same period last year.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ABEO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ABEO
Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 23.75 USD with a low forecast of 20.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.830
Low
20.00
Averages
23.75
High
27.50
Current: 4.830
Low
20.00
Averages
23.75
High
27.50
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High Insider Ownership Growth Companies in the U.S.
- High Insider Ownership: Super Micro Computer boasts 13.9% insider ownership while achieving 50.7% earnings growth, indicating strong performance and future growth potential in the tech sector.
- Profitability Improvement: Abeona Therapeutics recently became profitable with 10.3% insider ownership and is forecasted to grow revenue by 42.5% annually, enhancing its competitive position in gene and cell therapy.
- Market Expansion Potential: Streamex Corp. has 16.1% insider ownership and, despite a financial loss of $15.58 million, is projected to grow revenue by over 100% annually, showcasing its innovative capabilities in asset tokenization.
- Earnings Growth Expectations: Fiverr International, with 11.6% insider ownership, reported a net income of $5.54 million in Q3 2025, with projected earnings growth of 47.5% per year, reflecting strong momentum in the global online marketplace.
Continue Reading
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees as a significant inducement for employment, aimed at attracting and retaining key talent to support the company's growth.
- Equity Structure: According to Nasdaq listing rules, the awarded shares will vest annually on the anniversary of the grant date, ensuring employee retention over three years, which enhances team stability and execution capability.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product, which is the first autologous cell-based gene therapy for treating severe skin diseases, showcasing the company's innovative potential in the biopharmaceutical sector.
- Market Outlook: Through this equity incentive, Abeona not only enhances employee loyalty but also potentially increases its attractiveness in the highly competitive biopharmaceutical market, aiding the company in achieving its long-term growth objectives.
Continue Reading